News and Announcements
Alcidion Group Commercialises Miya Platform Throughout Australia & New Zealand & Secures $2.35m Contract with Western Health
- Published August 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Alcidion Group Limited (ASX:ALC) is pleased to provide a summary of its progress over the quarter ending 30 June 2017 and report on its cashflow over the same period.
KEY TAKEAWAYS:
- Significant milestones achieved in commercialising the Miya platform throughout Australia and New Zealand.
- Securing of a $AUD2.35m Contract with Western Health, crystallising a long term relationship with Western Health.
- Securing a $NZD1.60m Contract with Mid Central, the Company’s first deployment in New Zealand, paving the way for future engagement with the NZ Ministry of Health and the remaining District Health Boards.
- Securing a contract with the Northern Territory Department of Health to extend Miya Patient Flow across Katherine Hospital in the Northern Territory.
- Hosting initial discussions with Calvary Health Care over the deployment of the Miya platform across the group, with a focus on Revenue Optimisation and Analytics and securing an initial contract to develop a Data Lake for Calvary Health Care.
- Entered into preliminary discussions with North American Strategic Partners, with a view to reciprocal distribution agreements.
- The Company’s quarterly cash and cash equivalents reduced minimally by $114k.
- Strong Cash position with Cash and cash equivalents as of 30 June 2017 of $5.531 million, with minimal debt.
- Reviewed potential acquisition targets, with the view to accelerating the Company’s commercialisation strategy through leveraging cross selling opportunities.
Company Updates
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Backed By Leading Investment Groups and Family Offices
